ICPT - Intercept Pharmaceuticals

-

$undefined

N/A

(N/A)

Intercept Pharmaceuticals NASDAQ:ICPT Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

Location: | Website: www.interceptpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

126.6M

Avg Qtr Burn

N/A

Short % of Float

27.80%

Insider Ownership

3.13%

Institutional Own.

81.30%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCALIVA® (obeticholic acid) Details
Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease

Approved

Quarterly sales

Ocaliva + Bezafibrate Details
Primary biliary cholangitis, Liver disease

Phase 2

Update

INT-787 Details
Liver disease, Alcoholic hepatitis

Phase 2a

Update

Ocaliva Details
Primary sclerosing cholangitis, Liver disease

Failed

Discontinued

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued